â– LECTURE OVERVIEW: Competitive inhibition is a classical mechanism where a structural analog of a substrate binds reversibly to the active site of an enzyme, reducing the rate of reaction.
â– ENZYMATIC KINETICS & PROPERTIES:
1. Active Site Competition: The inhibitor competes directly with the substrate for the unoccupied active site of the free enzyme (E), forming an inactive enzyme-inhibitor complex (EI).
2. Kinship with Substrate: Because the inhibitor binds at the same site, competitive inhibition can be completely overcome by increasing the substrate concentration. At exceptionally high substrate concentrations, substrate molecules outcompete inhibitor molecules, occupying all active sites.
3. Vmax Unchanged: Because high substrate concentrations fully overcome competitive inhibition, the maximum velocity (Vmax) of the reaction remains completely unchanged.
4. Km Increased: The apparent Michaelis constant (Km) increases. Because the inhibitor is present, a higher concentration of substrate is required to achieve half of the maximum velocity (1/2 Vmax), representing a decreased apparent affinity of the enzyme for its substrate.
â– PROGNOSTIC CRITERIA & TIMELINE:
Patient outcome scales correlate heavily with diagnostic staging at presentation, age, pre-existing comorbidities, and biological markers of cellular dividing rates.
â– PHARMACODYNAMIC TARGET ENGAGEMENT:
Receptor binding dynamics dictate the overall speed, duration, and magnitude of physiological responses to therapeutic agents.
[HY-BOARD-1369]
🌟 Dynamic Clinical Key:
Statins (e.g., Atorvastatin, Rosuvastatin) are classic clinical examples of competitive reversible inhibitors. They structurally resemble HMG-CoA, competing for the active site of HMG-CoA Reductase (the rate-limiting enzyme in cholesterol synthesis) to lower systemic LDL production. Regularly reassess clinical parameters to adjust long-term therapy. Watch closely for ligand-receptor saturation effects and subsequent tolerance or resistance.